Andexanet Alfa in Urgent Cardiac Surgery: A Case Report of Edoxaban Reversal for Acute Hemopericardium.

BACKGROUND Antidotes to non-vitamin K oral anticoagulants (NOAK) like idarucizumab and andexanet alfa have been approved for reversing the effects of dabigatran and apixaban/rivaroxaban, respectively. However, andexanet alfa is not approved for reversing edoxaban. Current guidelines recommend using specific reversal agents in emergencies, but they do not support andexanet alfa for edoxaban reversal. This study illustrates the off-label use of andexanet alfa for edoxaban reversal in a case of acute hemopericardium requiring urgent cardiac surgery, addressing the practical challenges and clinical outcomes. CASE REPORT We report the case of a 71-year-old woman who required urgent cardiac surgery following acute pericardial tamponade caused by hemopericardium during right-heart catheterization. After emergency pericardiocentesis, andexanet alfa was administered to address any residual effects of edoxaban (Lixiana), along with protamine to reverse the effects of heparin. The patient was transferred in stable condition for cardiac surgery, where a right ventricular perforation responsible for the hemopericardium was sutured, and mitral valve replacement was performed via cardiopulmonary bypass (CPB) due to severe mitral valve regurgitation. No adverse cerebrovascular, hemorrhagic, or thromboembolic events were observed. CONCLUSIONS This case demonstrates an unconventional off-label use of andexanet alfa to stabilize a patient on edoxaban. Although the patient did not have any adverse effects, the thromboembolic risks of andexanet alfa and potential heparin resistance warrant cautious use, especially before cardiac surgery. Successful management was achieved through a multidisciplinary approach. Further research is needed to evaluate the safety and efficacy of andexanet alfa in patients on edoxaban therapy.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

BACKGROUND Antidotes to non-vitamin K oral anticoagulants (NOAK) like idarucizumab and andexanet alfa have been approved for reversing the effects of dabigatran and apixaban/rivaroxaban, respectively.

Leech-derived molecules this paper discusses, each with a full profile in the ASH compound registry:

Узнайте, как это исследование связано с клинической практикой

More peer-reviewed studies in Безопасность и инфекционный контроль.

• Leech-Assisted Flap Salvage — Systematic Review of 277 Cases — Whitaker et al. (2012)
• Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome — Bilden A et al. (2026)
• AIF-1 and RNASET2 Play Complementary Roles in the Innate Immune Response of Medicinal Leech — Baranzini N et al. (2019)
• [Hirudo medicinalis-leech applications in plastic and reconstructive microsurgery--a literature review] — Knobloch K et al. (2007)
• Bacterial symbioses of the medicinal leech Hirudo verbana — Nelson M, Graf J (2012)
• Leech related Aeromonas complex infection after reconstruction with a microvascular forearm flap — Beger B, von Loewenich F, Goetze E, Moergel M, Walter C (2016)
• Aeromonas septicemia after medicinal leech use following replantation of severed digits — Levine SM, Frangos SG, Hanna B, Colen K, Levine JP (2009)
• Outcomes of flap salvage with medicinal leech therapy — Nguyen MQ et al. (2012)
• The role of leech water sampling in choice of prophylactic antibiotics in medical leech therapy — Wilmer A et al. (2013)
• The development and application of mini-barcodes from mitochondrial DNA for identifying medicinal leeches from traditional medicines — Liu Y et al. (2025)

Browse all ASH-analysed research →